Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label pediatric etrasimod study in moderately to severely active ulcerative colitis
MOH_2025-11-30_015504Phase 2Not yet recruiting
- Sponsor
- Pfizer
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etrasimod in autoimmune colitis, sponsored by Pfizer. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
etrasimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2025-11-30_015504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-11-30_015504.